Search
CELL BANK Website

Back Back
Cell No. : Cell Name
RCB1280 : TGBC50TKB  update : 2020/09/24
Comment3 cell lines from different metastases were established from the same patient. See TGBC51TKB. Application consideration
Comment from the depositor
Terms and conditionsThere is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, a prior written permission of the DEPOSITOR or the RIKEN BRC is necessary.
Remarks
Order Form Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, Category I and II, depending on the sort of user institutions and the purposes of use.Please use an appropriate MTA(to see).In case of Restriction "a" or "f", please contact RIKEN BRC(cellbank.brc@riken.jp) regarding any kind of for-profit use.
Basic information Depositor Todoroki, T. & Ohno, T.
Originator Ohno, Tadao & Yasugi Tomoko
Year of deposit 1996
Another name YaKa
Animal human < Mammals
Genus Homo
Species sapiens
Race Japanese
Gender Male
Age at sampling 52 years
Tissue papilla vater, liver meta
Metastastatic ability Yes
Metastatsd tissue lymph node,peritoneu
Classification cancer
Year of origin 1996
Lifespan infinite
Morphology epithelial-like
deposit info
lot info
Medium Medium List
Culture type Adherent cells
Medium and additives DMEM (low glucose) + 10% FBS
Antibiotics Free
Passage method 0.25% trypsin
Culture information Passage ratio 1 : 4 split
SC frequency Subculture : once/10-14 days, Medium Renewal : 2 times/week
Temperature 37 ℃
CO2 concentration 5 %
Freeze medium Medium + 10% DMSO
Freezing method Slow freezing
Mycoplasma (-)
STR(human) OK
Virus (HBV) (-)
Virus (HCV) (-)
Isozyme LD, NP
Chromosome mode 66-72(50) : 66(1),67(10),68(8),69(10),70(13),71(6)/
Images
deposit info
lot info
Reference information Reference 0
User's Publication 2


To topTop
Reference

To topTop
User's Publication
3738  Yamashita-Kashima Y, Yoshimura Y, Fujimura T, Shu S, Yanagisawa M, Yorozu K, Furugaki K, Higuchi R, Shoda J, Harada N.  Molecular targeting of HER2-overexpressing biliary tract cancer cells with trastuzumab emtansine, an antibody-cytotoxic drug conjugate.  Cancer Chemother Pharmacol.  2019  83(4):659-671  PubMed ID: 30659304
9603  Lai ZW, Bolm L, Fuellgraf H, Biniossek ML, Makowiec F, Hopt UT, Werner M, Keck T, Bausch D, Sorio C, Scarpa A, Schilling O, Bronsert P, Wellner UF.  Characterization of various cell lines from different ampullary cancer subtypes and cancer associated fibroblast-mediated responses.  BMC Cancer  2016  16:195  PubMed ID: 26951071



Back Back Return Top Page